Literature DB >> 31002437

Newly Defined ATP-Binding Cassette Subfamily B Member 5 Positive Dermal Mesenchymal Stem Cells Promote Healing of Chronic Iron-Overload Wounds via Secretion of Interleukin-1 Receptor Antagonist.

Seppe Vander Beken1, Juliane C de Vries1, Barbara Meier-Schiesser1, Patrick Meyer1, Dongsheng Jiang1, Anca Sindrilaru1, Filipa F Ferreira1, Adelheid Hainzl1, Susanne Schatz1, Jana Muschhammer1, Natalie J Scheurmann1, Panagiotis Kampilafkos1, Andreas M Seitz2, Lutz Dürselen2, Anita Ignatius2, Mark A Kluth3,4, Christoph Ganss3,4, Meinhard Wlaschek1, Karmveer Singh1, Pallab Maity1, Natasha Y Frank5,6,7, Markus H Frank5,8,9,10, Karin Scharffetter-Kochanek1.   

Abstract

In this study, we report the beneficial effects of a newly identified dermal cell subpopulation expressing the ATP-binding cassette subfamily B member 5 (ABCB5) for the therapy of nonhealing wounds. Local administration of dermal ABCB5+ -derived mesenchymal stem cells (MSCs) attenuated macrophage-dominated inflammation and thereby accelerated healing of full-thickness excisional wounds in the iron-overload mouse model mimicking the nonhealing state of human venous leg ulcers. The observed beneficial effects were due to interleukin-1 receptor antagonist (IL-1RA) secreted by ABCB5+ -derived MSCs, which dampened inflammation and shifted the prevalence of unrestrained proinflammatory M1 macrophages toward repair promoting anti-inflammatory M2 macrophages at the wound site. The beneficial anti-inflammatory effect of IL-1RA released from ABCB5+ -derived MSCs on human wound macrophages was conserved in humanized NOD-scid IL2rγ null mice. In conclusion, human dermal ABCB5+ cells represent a novel, easily accessible, and marker-enriched source of MSCs, which holds substantial promise to successfully treat chronic nonhealing wounds in humans. Stem Cells 2019;37:1057-1074.
© 2019 The Authors. Stem Cells published by Wiley Periodicals, Inc. on behalf of AlphaMed Press 2019.

Entities:  

Keywords:  Cell surface markers; Clinical translation; Mesenchymal stem cells; Tissue regeneration; Tissue-specific stem cells; Xenotransplantation

Mesh:

Substances:

Year:  2019        PMID: 31002437      PMCID: PMC6663647          DOI: 10.1002/stem.3022

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  50 in total

Review 1.  Functional heterogeneity of mesenchymal stem cells: implications for cell therapy.

Authors:  Donald G Phinney
Journal:  J Cell Biochem       Date:  2012-09       Impact factor: 4.429

2.  Propagation, expansion, and multilineage differentiation of human somatic stem cells from dermal progenitors.

Authors:  Georg Bartsch; James J Yoo; Paolo De Coppi; M Minhaj Siddiqui; Gunter Schuch; Hans G Pohl; Jasmin Fuhr; Laura Perin; Shay Soker; Anthony Atala
Journal:  Stem Cells Dev       Date:  2005-06       Impact factor: 3.272

3.  SSEA-4 identifies mesenchymal stem cells from bone marrow.

Authors:  Eun J Gang; Darko Bosnakovski; Camila A Figueiredo; Jan W Visser; Rita C R Perlingeiro
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

4.  Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury.

Authors:  Hideaki Nakajima; Kenzo Uchida; Alexander Rodriguez Guerrero; Shuji Watanabe; Daisuke Sugita; Naoto Takeura; Ai Yoshida; Guang Long; Karina T Wright; William E B Johnson; Hisatoshi Baba
Journal:  J Neurotrauma       Date:  2012-04-18       Impact factor: 5.269

5.  Human skin wounds: a major and snowballing threat to public health and the economy.

Authors:  Chandan K Sen; Gayle M Gordillo; Sashwati Roy; Robert Kirsner; Lynn Lambert; Thomas K Hunt; Finn Gottrup; Geoffrey C Gurtner; Michael T Longaker
Journal:  Wound Repair Regen       Date:  2009 Nov-Dec       Impact factor: 3.617

6.  Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile.

Authors:  Julian Maggini; Gerardo Mirkin; Ianina Bognanni; Josefina Holmberg; Isabel M Piazzón; Irene Nepomnaschy; Héctor Costa; Cristian Cañones; Silvina Raiden; Mónica Vermeulen; Jorge R Geffner
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

7.  ABCB5 is a limbal stem cell gene required for corneal development and repair.

Authors:  Bruce R Ksander; Paraskevi E Kolovou; Brian J Wilson; Karim R Saab; Qin Guo; Jie Ma; Sean P McGuire; Meredith S Gregory; William J B Vincent; Victor L Perez; Fernando Cruz-Guilloty; Winston W Y Kao; Mindy K Call; Budd A Tucker; Qian Zhan; George F Murphy; Kira L Lathrop; Clemens Alt; Luke J Mortensen; Charles P Lin; James D Zieske; Markus H Frank; Natasha Y Frank
Journal:  Nature       Date:  2014-07-02       Impact factor: 49.962

8.  TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds.

Authors:  Yu Qi; Dongsheng Jiang; Anca Sindrilaru; Agatha Stegemann; Susanne Schatz; Nicolai Treiber; Markus Rojewski; Hubert Schrezenmeier; Seppe Vander Beken; Meinhard Wlaschek; Markus Böhm; Andreas Seitz; Natalie Scholz; Lutz Dürselen; Jürgen Brinckmann; Anita Ignatius; Karin Scharffetter-Kochanek
Journal:  J Invest Dermatol       Date:  2013-08-06       Impact factor: 8.551

Review 9.  Disclosure of the Culprits: Macrophages-Versatile Regulators of Wound Healing.

Authors:  Anca Sindrilaru; Karin Scharffetter-Kochanek
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-09       Impact factor: 4.730

10.  Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes.

Authors:  Rita E Mirza; Milie M Fang; William J Ennis; Timothy J Koh
Journal:  Diabetes       Date:  2013-03-14       Impact factor: 9.461

View more
  15 in total

1.  Expression of the Stem Cell Marker ABCB5 in Normal and Tumor Tissues.

Authors:  Mohamed E M Saeed; Joelle C Boulos; Kevin Machel; Nasim Andabili; Thamail Marouni; Wilfried Roth; Thomas Efferth
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 2.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

3.  ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment.

Authors:  Julia Riedl; Michael Pickett-Leonard; Cindy Eide; Mark Andreas Kluth; Christoph Ganss; Natasha Y Frank; Markus H Frank; Christen L Ebens; Jakub Tolar
Journal:  Stem Cells       Date:  2021-03-01       Impact factor: 5.845

4.  Potential Therapeutic Effects of Long-Term Stem Cell Administration: Impact on the Gene Profile and Kidney Function of PKD/Mhm (Cy/+) Rats.

Authors:  Daniela Nardozi; Stefania Palumbo; Arif Ul Maula Khan; Carsten Sticht; Karen Bieback; Samar Sadeghi; Mark Andreas Kluth; Michael Keese; Norbert Gretz
Journal:  J Clin Med       Date:  2022-05-05       Impact factor: 4.241

5.  TLR4-dependent shaping of the wound site by MSCs accelerates wound healing.

Authors:  Saira Munir; Abhijit Basu; Pallab Maity; Linda Krug; Philipp Haas; Dongsheng Jiang; Gudrun Strauss; Meinhard Wlaschek; Hartmut Geiger; Karmveer Singh; Karin Scharffetter-Kochanek
Journal:  EMBO Rep       Date:  2020-03-12       Impact factor: 8.807

6.  Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: evidence from meta-analysis of transcriptomic data.

Authors:  Luke H Stockwin
Journal:  PeerJ       Date:  2020-06-19       Impact factor: 2.984

7.  Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Kathrin Dieter; Elke Niebergall-Roth; Silvia Fluhr; Cristina Daniele; Jasmina Esterlechner; Samar Sadeghi; Seda Ballikaya; Leoni Erdinger; Franziska Schauer; Stella Gewert; Martin Laimer; Johann W Bauer; Alain Hovnanian; Giovanna Zambruno; May El Hachem; Emmanuelle Bourrat; Maria Papanikolaou; Gabriela Petrof; Sophie Kitzmüller; Christen L Ebens; Markus H Frank; Natasha Y Frank; Christoph Ganss; Anna E Martinez; John A McGrath; Jakub Tolar; Mark A Kluth
Journal:  JCI Insight       Date:  2021-11-22

Review 8.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

9.  Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP.

Authors:  Seda Ballikaya; Samar Sadeghi; Elke Niebergall-Roth; Laura Nimtz; Jens Frindert; Alexandra Norrick; Nicole Stemler; Nicole Bauer; Yvonne Rosche; Vanessa Kratzenberg; Julia Pieper; Tina Ficek; Markus H Frank; Christoph Ganss; Jasmina Esterlechner; Mark A Kluth
Journal:  Stem Cell Res Ther       Date:  2020-11-16       Impact factor: 6.832

10.  Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data.

Authors:  Andreas Kerstan; Elke Niebergall-Roth; Jasmina Esterlechner; Hannes M Schröder; Martin Gasser; Ana M Waaga-Gasser; Matthias Goebeler; Katrin Rak; Philipp Schrüfer; Sabrina Endres; Petra Hagenbusch; Korinna Kraft; Kathrin Dieter; Seda Ballikaya; Nicole Stemler; Samar Sadeghi; Nils Tappenbeck; George F Murphy; Dennis P Orgill; Natasha Y Frank; Christoph Ganss; Karin Scharffetter-Kochanek; Markus H Frank; Mark A Kluth
Journal:  Cytotherapy       Date:  2020-10-01       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.